Medical Advocates
Dolutegravir (Tivicay/S/GSK1349572)
  Conference Reports, Abstracts,  and Posters

 XX International AIDS Conference
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention
XIX International AIDS Conference
6th_IAS_Conference_on_HIV_Pathogenesis,_Treatment_and_Prevention

 		  
Dolutegravir Main Page Main New/Newsworthy  Home Page      
Last Update:  December 08, 2014 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 
XX International AIDS Conference
     
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention
     

 
  • A WEEK-IN-REVIEW FEATURED REPORT
    POST    ER
     HIV resistance to dolutegravir (DTG) simultaneously diminishes viral DNA integration into host cells and viral replication fitness: implications for HIV reservoirs
         T. Mesplede, P. Quashie M. Oliveira, M. Wainberg
    Poster         Abstract
  • POSTER
         Secondary resistance mutations in the R263K integrase inhibitor resistance pathway
    T. Mesplède, M.A. Wares, N. Osman, P.K. et ak
    Paper      Abstract
  • Dolutegravir is non-inferior to raltegravir and shows durable response through 96 weeks: results from the SPRING-2 trial
    F. Raffi, H. Jaeger, D. Motta, et al
     Abstract
  • Once-daily dolutegravir (DTG; S/GSK1349572) has a renal safety profile comparable to raltegravir (RAL) and efavirenz in antiretroviral (ART)‑naïve adults: 48 week results from SPRING-2 (ING113086) and SINGLE (ING114467)
    L.D. Curtis, S. Min, G. Nichols, et al
  • Dolutegravir (DTG) is superior to raltegravir (RAL) in ART-experienced, integrase naive subjects: week 48 results from SAILING (ING111762)
    P. Cahn, A.L. Pozniak, H. Mingrone3,et al
XIX International AIDS Conference
     
  • Pharmacokinetics, safety and efficacy of dolutegravir (DTG; S/GSK1349572) in HIV-1-positive adolescents: preliminary analysis from IMPAACT P1093
    R. Hazra, R. Viani, E. Acosta, et al
     Abstract
  • A WEEK-IN-REVIEW FEATURED REPORT
    Once-daily dolutegravir (DTG; S/GSK1349572) is non-inferior to raltegravir (RAL) in antiretroviral‑naive adults: 48 week results from SPRING-2 (ING113086)
    F. Raffi, A. Rachlis2 H.-J. Stellbrink, et al
     Abstract
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention
     
  • Increasing patient compliance in SPRING-1 phase IIb HIV clinical trial in ART-naïve patients with dolutegravir (DTG, S/GSK1349572)
    J. Harris, S. Hughes, C. Brothers
    Abstract
  • Rapid, robust and sustained antiviral response with once-daily (QD) dolutegravir (DTG, S/GSK1349572), a next generation integrase inhibitor (INI) in combination therapy in antiretroviral-naïve adults: 48 week results from SPRING-1 (ING112276)
    J. Van Lunzen, F. Maggiolo, B. Phung, et al
     Abstract
  • No impact of HIV integrase polymorphisms at position 101 and 124 on in vitro resistance isolation with dolutegravir (DTG, S/GSK1349572), a potent next generation HIV integrase inhibitor
    T. Seki, S. Miki, M. Kobayashi, T. Yoshinaga
     Abstract
  • Safety profile of dolutegravir (DTG, S/GSK1349572), in combination with other antiretrovirals in antiretroviral (ART)-naïve and ART-experienced adults from two phase IIb studies
    S. Min, A. Carrod, L. Curtis, C. Stainsby
     Abstract

Dolutegravir Main Page Main New/Newsworthy  Home Page      

Dolutegravir (Tivicay/S/GSK139572)
 Conference Reports, Abstracts,  and Posters